Grants Search Results

This institution is a member of a research consortium which is being funded by St. Baldrick's: New Approaches to Neuroblastoma Therapy (NANT) Consortium. For a description of this project, see the consortium grant made to the lead institution: Children's Hospital Los Angeles, Los Angeles, CA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: New Approaches to Neuroblastoma Therapy (NANT) Consortium. For a description of this project, see the consortium grant made to the lead institution: Children's Hospital Los Angeles, Los Angeles, CA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: New Approaches to Neuroblastoma Therapy (NANT) Consortium. For a description of this project, see the consortium grant made to the lead institution: Children's Hospital Los Angeles, Los Angeles, CA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: New Approaches to Neuroblastoma Therapy (NANT) Consortium. For a description of this project, see the consortium grant made to the lead institution: Children's Hospital Los Angeles, Los Angeles, CA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: New Approaches to Neuroblastoma Therapy (NANT) Consortium. For a description of this project, see the consortium grant made to the lead institution: Children's Hospital Los Angeles, Los Angeles, CA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: New Approaches to Neuroblastoma Therapy (NANT) Consortium. For a description of this project, see the consortium grant made to the lead institution: Children's Hospital Los Angeles, Los Angeles, CA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: New Approaches to Neuroblastoma Therapy (NANT) Consortium. For a description of this project, see the consortium grant made to the lead institution: Children's Hospital Los Angeles, Los Angeles, CA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: New Approaches to Neuroblastoma Therapy (NANT) Consortium. For a description of this project, see the consortium grant made to the lead institution: Children's Hospital Los Angeles, Los Angeles, CA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: New Approaches to Neuroblastoma Therapy (NANT) Consortium. For a description of this project, see the consortium grant made to the lead institution: Children's Hospital Los Angeles, Los Angeles, CA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: New Approaches to Neuroblastoma Therapy (NANT) Consortium. For a description of this project, see the consortium grant made to the lead institution: Children's Hospital Los Angeles, Los Angeles, CA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: New Approaches to Neuroblastoma Therapy (NANT) Consortium. For a description of this project, see the consortium grant made to the lead institution: Children's Hospital Los Angeles, Los Angeles, CA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: New Approaches to Neuroblastoma Therapy (NANT) Consortium. For a description of this project, see the consortium grant made to the lead institution: Children's Hospital Los Angeles, Los Angeles, CA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: New Approaches to Neuroblastoma Therapy (NANT) Consortium. For a description of this project, see the consortium grant made to the lead institution: Children's Hospital Los Angeles, Los Angeles, CA.

Based on progress to date, Dr. Shand was awarded new grants in 2017 and 2018 to fund additional years of this Scholar award. Leukemia is a blood cancer that kills more children than any other cancer. Dr. Shand's work is based on the belief that leukemia behaves like some infections do, by tricking our body into thinking it's OK to set up shop there. Dr. Shand is studying how leukemia can send these "trick signals" to the part of our body that fights off infections, the immune system. This research aims to understand how these trick signals work, with the goal of turning them off so that the immune system can be used to cure leukemia.

This grant is generously supported by Micaela's Army Foundation, a St. Baldrick's partner which was founded in loving memory of Micaela White who fiercely fought Acute Myeloid Leukemia at the age of 18. Their mission is to raise money to help fund cancer research, education, awareness, and patient support for the cancers that affect children and their families.

Children who are successfully treated for cancer sometimes develop a second cancer due to treatment with radiation and chemotherapy drugs. Leukemia is one of the most common types of secondary cancer, and treatment-induced leukemia is extremely aggressive and very hard to cure. Chromosome 7 is often deleted in this type of leukemia. Dr. Shannon recently created models with deletions similar to those found in children with treatment-induced leukemia. With the Kenneth and Mary Ellen Wilson St. Baldick's Research Grant, Dr. Shannon is using these models to understand how these leukemias develop, why they are so hard to treat, and to test new therapies.

This grant is named in memory of Kenneth and Mary Ellen Wilson, parents of Todd and Jason Alonzo. Their legacy of giving and generosity lives on in the service and dedication of their children.

Rhabdomyosarcoma is the most common soft tissue sarcoma in children. Dr. Shern's group recently discovered that mutations in 10 genes drive this disease. This research grant is determining whether these mutations can be used as markers of prognosis or response to therapy. Dr. Shern hopes to develop a tool that can be used to better detect and treat rhabdomyosarcoma. If successful, the developed tool can immediately be integrated into clinical trials to improve the current therapy.

This grant is made with generous support from the PFP Fund for Cancer Research, a St. Baldrick's Hero Fund created in memory of Peyton Arens and honors his fighting spirit by supporting research that will bring about cures and less toxic treatments.

Based on progress to date, Dr. Stieglitz was awarded a new grant in 2016 to fund an additional year of this Fellow award. Juvenile myelomonocytic leukemia (JMML) is a type of blood cancer that affects young children and is very difficult to treat. Currently available treatments cure only half of these patients, with some children experiencing rapid death, while others get better with very little treatment. Unfortunately, no one knows why this happens. Dr. Stieglitz is using the latest breakthroughs in scientific technology to determine why some patients benefit from treatment while others do not.

Better therapies that specifically target cancer cells while leaving normal cells undamaged will lead to therapies with fewer short or long term side effects. Cancer, specifically Ewing sarcoma, changes how proteins are made. New proteins occur by rearranging the messages that come from DNA. The rearranged messages turn into proteins that keep the cancer growing. Dr. Toretsky's research aims to find out what the rearranged messages are and how the new proteins could be targeted with new medicines.

This grant is made with generous support from the Team Clarkie Fund, a St. Baldrick's Hero Fund created to honor Clarkie Carroll. It will fund Ewing sarcoma research while stimulating greater awareness and inspiring others to believe pediatric cancer research can and will lead to a cure.

Improving the outcome of aggressive childhood leukemias depends on developing new targeted treatments. With the NetApp St. Baldrick's Research Grant, Dr. Wechsler is studying a mutant gene called CALM-AF10 that causes high-risk leukemias in children. They determined that the leukemia-causing properties of this gene depend on its interaction with a partner protein called CRM1. This research is studying the mechanisms by which CRM1 enables CALM-AF10 to cause leukemias, and the ability of drugs to inhibit CRM1 to stop leukemia growth.

This grant is named for the NetApp team, whose offices around the world have raised more than $5.8 million since 2007 for life-saving research through the St. Baldrick's Foundation.

While many children with leukemia experience good outcomes on modern therapies, there are a large number of children who still relapse and die of their disease. Using new methods, Dr. Willman identified a new form of leukemia, called Ph-like ALL, which has a variety of gene mutations which code for enzymes. Currently, drugs that inhibit these enzymes are available for clinical trials. Dr. Willman is testing these drugs in children with high risk leukemia. This research aims to extend Dr. Willman's current studies to include children with standard risk leukemia in order to also improve their chances of survival.